ROCKY MOUNTAIN CANCER CENTERS
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- -
- Market Cap
- -
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Definitive Therapy for Oligometastatic Solid Malignancies
- Conditions
- Stage IV or Recurrent Carcinoma or Sarcoma
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Rocky Mountain Cancer Centers
- Target Recruit Count
- 110
- Registration Number
- NCT01898962
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers - Boulder, Boulder, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers - Littleton, Littleton, Colorado, United States
Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Rocky Mountain Cancer Centers
- Registration Number
- NCT01409473
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers - Littleton, Littleton, Colorado, United States
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
- Conditions
- Breast Cancer
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Rocky Mountain Cancer Centers
- Target Recruit Count
- 660
- Registration Number
- NCT01185132
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers - Boulder, Boulder, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers - Lakewood, Lakewood, Colorado, United States
Accelerated Partial Breast Radiotherapy With Either Mammosite or Intensity Modulated Radiotherapy
- Conditions
- Breast Cancer
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Rocky Mountain Cancer Centers
- Target Recruit Count
- 291
- Registration Number
- NCT01185145
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers - Boulder, Boulder, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers - Midtown, Denver, Colorado, United States
Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol
- Conditions
- Renal DysfunctionAcute Renal FailureMortality
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2008-06-03
- Lead Sponsor
- Rocky Mountain Cancer Centers
- Target Recruit Count
- 20
- Registration Number
- NCT00390624
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers 1800 Williams Street, Suite 200, Denver, Colorado, United States
News
PSMA PET Imaging Transforms Prostate Cancer Management with Multiple FDA-Approved Agents
PSMA PET imaging has revolutionized prostate cancer detection and management, particularly in biochemical recurrence settings, with multiple FDA-approved agents now available including gallium-68 PSMA-11, piflufolastat F 18, and flotufolastat F 18.
Survey Reveals Challenges in Venetoclax Adoption for CLL Treatment in Community Settings
A recent survey of 103 oncologist-hematologists shows tumor lysis syndrome management and clinical logistics are primary concerns in venetoclax initiation for CLL treatment.
Mosunetuzumab Shows Promise in Follicular Lymphoma, Ongoing Trials Explore Efficacy
Mosunetuzumab demonstrates a high objective response rate of 95% and a complete metabolic response rate of 83.3% in previously untreated, low-tumor burden follicular lymphoma patients.
Expert Outlines Strategies to Improve Access and Diversity in HR+/HER2- Breast Cancer Clinical Trials
Dr. Mabel Mardones emphasizes the critical importance of bringing clinical trials to community settings, highlighting the need for collaboration between pharmaceutical companies, academic centers, and community practices.
Oncology Leaders Emphasize Cautious AI Implementation to Maintain Physician Trust
Rocky Mountain Cancer Centers' executive director warns that inaccurate AI outputs could damage physician confidence in the technology for months, emphasizing the need for careful implementation.